Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson experiences first quarter growth

Johnson and Johnson experiences first quarter growth

21st April 2010

Johnson and Johnson has reported year-on-year improvements in fiscal performance during the first quarter of 2010, with its medical devices unit playing a key role.

The group’s overall sales total for the three-month period came to $15.6 billion (10.1 billion pounds), a four per cent increase on the first quarter of 2009, while worldwide medical devices and diagnostics sales grew by 12.5 per cent.

Strong sales of subsidiary DePuy’s orthopaedic joint reconstruction and sports medicines were cited as a key contributor to this, as was the improved performance exhibited by Ethicon and Ortho-Clinical Diagnostics.

The company also highlighted the filing for CE Mark accreditation for the Nevo sirolimus-eluting coronary stent as a mark of progress during the quarter.

William Weldon, chairman and chief executive officer, said: “Thanks to the outstanding efforts of our people, we were able to deliver solid financial results.”

Earlier this month, the group’s subsidiary Cordis began a new clinical trial of Incraft, a new stent system designed to treat abdominal aortic aneurysm.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.